For more than three decades, scientists have been racing to stop Alzheimer's disease by removing amyloid beta plaques - sticky clumps of toxic protein that accumulate in the brain.

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both ...

For Alzheimer’s, blood tests for p-tau are still useful, but they should not be the only method for diagnosis. A positive ...

Researchers at Northwestern University have made a breakthrough in identifying a way for Alzheimer's disease to be treated ...

Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia.

The results of a new study show that suppressing KCTD20, which responds to the neurotransmitter glutamate, activates a mechanism for expelling tau proteins.

Older women who take menopausal hormone therapy may be at a higher risk of Alzheimer's. A study published in Science Advances ...

The neurotransmitter glutamate is essential for regulating everything from mood to memory, but it can also encourage a toxic buildup of protein, which can contribute to Alzheimer's and related ...

In case you needed more bad news lately, yet another new study revealed that a common health condition may be linked with ...

"Studies have shown that vulnerability to Alzheimer's-related changes in the brain increase in women from pre- to ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

Elevated levels of p-tau 181 and 217 in cerebrospinal fluid are considered to reflect early Alzheimer's disease pathology.